Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients

Inflammopharmacology

Volumn 20, Issue 6, 2012, Pages 323-330

  Zivojinovic, Sladjana ^a,b   Pejnovic, Nada ^a   Sefik Bukilica, Mirjana ^a   Kovacevic, Ljiljana ^b   Soldatovic, Ivan ^a   Bugarski, Diana ^a   Mojsilovic, Slavko ^a   Damjanov, Nemanja ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE OF RHEUMATOLOGY   (Serbia)

Author keywords

Lipopolysaccharide; Rheumatoid arthritis; Th17 cytokines; Tumour necrosis factor a inhibitor; Whole blood cells

Indexed keywords

AUTOANTIBODY; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VIMENTIN;

ADULT; AGED; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DAS28; DISEASE MARKER; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TH17 CELL; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INTERLEUKINS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872158485     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0143-7     Document Type: Article

References (32)

1. Arnett FC, Edworthy SM, Bloch DA et al (1998) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
2. Benwell RK, Lee DR (2010) Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligandactivated dendritic cells. Clin Immunol 134:178-187
3. Burger D, Dayer JM, Palmer G, Gabay C (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20(5):879-896
4. Caporali R, Bobbio Pallavicini F, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274-280
5. Chatzantoni K, Mouzaki A (2006) Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top Med Chem 6:1707-1714
6. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2011) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti- TNF-a therapy. Arthritis Res Ther 13(4):R126
7. Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10:479-489
8. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226:87-102
9. González-Navajas JM, Fine S, Law J, Datta SK, Nguyen KP, Yu M, Corr M, Katakura K, Eckman L, Lee J, Raz E (2010) TLR4 signaling in effector CD4 ? T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 120:570-581
10. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, Saraux A, Roux-Lombard P, Mariette X (2012) Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 71(7):1243-1248
11. Hayashi EA, Granato A, Paiva LS, Bertho AL, Bellio M, Nobrega A (2010) TLR4 promotes B cell maturation: independence and cooperation with B lymphocyte-activating factor. J Immunol 184:4662-4672
12. Jovanovic DV, Di Battista JA, Martel-Pelletier J et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513-3521
13. Kageyama Y, Ichikawa T, Nagafusa T et al (2007) Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int 28:137-143
14. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(9664):659-672. doi:10.1016/S0140-6736(09)60008-8
15. Kuchen S, Robbins R, Sims GP et al (2007) Essential role of IL-21 in B cell activation CD4 ? T cell-B cell collaboration expansion, and plasma cell generation during CD4 ? T cell-B cell collaboration. J Immunol 179:5886-5896
16. Kwok SK, Cho ML, Park MK, Oh HJ, Park JS, Her YM, Lee SY, Youn J, Ju JH, Park KS, Kim SI, Kim HY, Park SH (2012) Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum 64(3):740-751
17. Lubberts E (2010) Th17 cytokines and arthritis. Semin Immunopathol 32:43-53
18. Myrianthefsa P, Karatzasa S, Venetsanoua K et al (2003) Seasonal variation in whole blood cytokine production after LPS stimulation in normal individuals. Cytokine 24:286-292
19. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, Dong C, Chen G (2010) IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 71(4):334-341
20. Paleolog E (2003) The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 12:1087-1095
21. Parker LC, Whyte MKB, Dower SK, Sabroe I (2005) The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol 77:886-892
22. Petrovic-Rackov L, Pejnovic N (2006) Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 25:448-452
23. Pincus T, Summey JA, Soraci SA Jr et al (1983) Assessment of patient satisfaction in activities of daily living using a Modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346-1353
24. Popa C, Barrera P, Joosten LA, van Riel PL, Kullberg BJ, van der Meer JW, Netea MG (2009) Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur Cytokine Netw 20(2): 88-93
25. Scallon B, Cai A, Solowski N, Rosenberg A, Song X-Y, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426
26. Shahrara S, Huang Q, Mandelin AM II, Pope RM (2008) TH-17 cells in rheumatoid arthritis. Arthritis Res Therapy 10:R93
27. Swaak AJ, van den Brink HG, Aarden LA (1997) Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis. Ann Rheum Dis 56(11):693-695
28. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergizes with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 61:870-876
29. van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheum 5(10):549-553
30. van Gestel AM, Prevoo ML, van't Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39:34-40
31. Young DA, Hegen M, Margery Ma HL et al (2007) Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56(4):1152-1163
32. Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS (2012) TNF blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J Rheum 39:18-21